Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Amortizatization of Intangibles (2020 - 2025)

Crescent Biopharma (CBIO) has disclosed Amortizatization of Intangibles for 7 consecutive years, with $95000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles changed N/A to $95000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $118000.0, a N/A change, with the full-year FY2025 number at $212000.0, down 47.35% from a year prior.
  • Amortizatization of Intangibles was $95000.0 for Q4 2025 at Crescent Biopharma, up from -$146571.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $227190.0 in Q3 2023 to a low of -$146571.0 in Q2 2025.
  • A 5-year average of $169885.9 and a median of $194078.0 in 2021 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: grew 10.21% in 2023, then dropped 22.61% in 2024.
  • Crescent Biopharma's Amortizatization of Intangibles stood at $194078.0 in 2021, then rose by 10.19% to $213848.0 in 2022, then dropped by 12.33% to $187482.0 in 2023, then decreased by 9.55% to $169571.0 in 2024, then plummeted by 43.98% to $95000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Amortizatization of Intangibles are $95000.0 (Q4 2025), -$146571.0 (Q2 2025), and $169571.0 (Q1 2024).